BRU •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 17:10
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeBRU
Market Capitalization123.2 mln
Float11.47 mln
Earnings Date09/24/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-2.09
Caution advised
Relative Strength
36
/ 100
Underperforming
Debt / Equity
0.06
Debt-free
ROE
-21.71
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Hyloris Pharmaceuticals is a Belgian drug development company focused on creating improved versions of existing medicines to fill gaps in patient care. Founded in 2012 and based in Liège, the company has built a broad portfolio spanning pain management, heart conditions, infections, and several other therapeutic areas. Hyloris works with a number of partner organizations to bring its products to market and currently has multiple treatments either available or in development.
